Atossa Genetics (NASDAQ:ATOS) Posts Quarterly Earnings Results, Misses Expectations By $0.29 EPS

Atossa Genetics (NASDAQ:ATOS) released its earnings results on Wednesday. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.29), FiscalAI reports.

Atossa Genetics Stock Performance

ATOS stock traded down $0.09 during midday trading on Wednesday, reaching $5.42. The company’s stock had a trading volume of 129,381 shares, compared to its average volume of 145,913. Atossa Genetics has a 1 year low of $3.76 and a 1 year high of $19.35. The firm has a market capitalization of $46.67 million, a price-to-earnings ratio of -1.51 and a beta of 1.42. The stock has a fifty day simple moving average of $5.95 and a two-hundred day simple moving average of $10.05.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Atossa Genetics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after purchasing an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. bought a new position in shares of Atossa Genetics during the second quarter valued at approximately $2,468,000. Renaissance Technologies LLC increased its holdings in Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after buying an additional 514,175 shares during the period. Geode Capital Management LLC increased its holdings in Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after buying an additional 9,627 shares during the period. Finally, State Street Corp raised its stake in Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after buying an additional 141,990 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ATOS has been the topic of several analyst reports. Ascendiant Capital Markets upped their price target on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Atossa Genetics presently has an average rating of “Hold” and a consensus target price of $95.00.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.